Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Malignant melanoma resisting vaccine composition and application thereof

A technology of malignant melanoma and vaccine composition, applied in the field of biopharmaceuticals, can solve the problem of increasing the specific anti-tumor immune response of malignant melanoma vaccine, inability to effectively induce or activate the patient's immune response, malignant melanoma specificity and immune response Weak response and other problems, to achieve strong specific killing function, good therapeutic effect, and easy to use

Active Publication Date: 2015-02-18
FIRST HOSPITAL AFFILIATED TO GENERAL HOSPITAL OF PLA
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when using inactivated tumor cells or crushing them as tumor vaccines to treat malignant melanoma, the immunogenicity of the tumor is too low to induce an effective anti-tumor immune response in the body. It can be seen that the specificity and immune response of malignant melanoma are weak, and the immune response of patients cannot be effectively induced or activated
[0003] Therefore, the current question is how to increase the specific anti-tumor immune response of malignant melanoma vaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Malignant melanoma resisting vaccine composition and application thereof
  • Malignant melanoma resisting vaccine composition and application thereof
  • Malignant melanoma resisting vaccine composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] 1. Preparation of malignant melanoma antigen

[0041] (1) Preparation of malignant melanoma attenuated cells

[0042] M3 malignant melanoma cell line (H-2 d )(2xl0 6 / mL) into a 6-well plate, and then 60 Co irradiation 30Gy spare.

[0043] (2) Preparation of DNP-modified malignant melanoma attenuated cells

[0044] M3 malignant melanoma cell line (H-2 d )(2xl0 6 / mL) into a 6-well plate, and then 100L of DNP solution to a final concentration of 0.2% (5mmol / L, pH7.2), incubated at 37°C for 10min, and then 60 Co irradiation 30Gy spare.

[0045] 2. Preparation of antigen mixture containing tuberculosis antigen, malignant melanoma antigen and rod-shaped bodies

[0046] Take the malignant melanoma antigen according to the amount of 80%-100% (volume), take the tuberculosis antigen according to the amount of 0%-20% (volume), and take the rod-shaped bodies according to the amount of 0%-20% (volume) and mix them evenly Backup.

[0047] 3. Preparation and activation of DC...

Embodiment 2

[0088] 1. Preparation of malignant melanoma antigen

[0089] (1) Preparation of malignant melanoma attenuated cells

[0090] The logarithmic growth of malignant melanoma cell line B16 (H-2 b )(1xl0 7 / mL) into a 6-well plate, and then 60 Co irradiation 30Gy spare.

[0091] (2) Preparation of DNP-modified malignant melanoma attenuated cells

[0092] The logarithmic growth of malignant melanoma cell line B16 (H-2 b )(1xl0 7 / mL) into a 6-well plate, and then 100 μL of DNP solution to a final concentration of 0.2% (5mmol / L, pH7.2), incubated at 37°C for 10min, and then 60 Co irradiation 30Gy standby, dose rate 1.88Gy / min.

[0093] 2. Preparation of antigen mixture containing tuberculosis antigen, malignant melanoma antigen and rod-shaped bodies

[0094] Take malignant melanoma antigen B16 attenuated cells according to the amount of 80%-98% (volume), take tuberculosis antigen BCG according to the amount of 2%-10% (volume), and take rod-shaped small Mix well and set aside. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to malignant melanoma resisting vaccine composition which is prepared through mixed culture of an antigen mixture and dendritic cell culture, wherein the antigen mixture comprises malignant melanoma antigens and tuberculosis antigens and / or Auer bodies. The vaccine composition can better stimulate specific T cell proliferation inside the body, has very high specificity killing function on targeted malignant melanoma cells, is convenient to use and good in treatment effect and has good application prospect.

Description

technical field [0001] The invention relates to the technical field of biopharmaceuticals, and relates to an anti-malignant melanoma vaccine composition and its application. Background technique [0002] Malignant melanoma is a malignant tumor with high degree of malignancy, easy metastasis, poor prognosis, insensitive to chemotherapy and radiotherapy, and high mortality rate. The disease mainly occurs in the skin, accounting for the third place in skin malignancies. With the rapid development of modern tumor immunology, immunotherapy aimed at the occurrence, development and metastasis of malignant melanoma has become a hot research topic. Although malignant melanoma is not sensitive to radiotherapy and chemotherapy, it is a tumor with high immunogenicity, so tumor vaccine and immune factor therapy are widely used. However, when using inactivated tumor cells or crushing them as a tumor vaccine to treat malignant melanoma, the immunogenicity of the tumor is too low to induc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/04A61K39/00A61P35/00
Inventor 杜楠李晓松赵辉陈殿君
Owner FIRST HOSPITAL AFFILIATED TO GENERAL HOSPITAL OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com